Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes

Background To study the visual outcomes of neovascular AMD (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) drugs at national level. Methods Multicenter national database of nAMD eyes treated with anti‐VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental ophthalmology 2022-04, Vol.50 (3), p.312-324
Main Authors: Zarranz‐Ventura, Javier, Nguyen, Vuong, Garay‐Aramburu, Gonzaga, Puzo, Martín, Arruabarrena, Carolina, Figueras‐Roca, Marc, Gillies, Mark C., Ventura, Javier Zarranz, Carrillo, Alba Parrado, Roca, Marc Figueras, Udina, Aina Moll, Serra, Jordi Izquierdo, Morales, Carolina Bernal, Alforja, Socorro, Casaroli Marano, Ricardo P., Ramsay, Laura Sararols, Londoño, Gabriel, Bañon, Karim, Rethati, Cynthia, Sánchez, Jorge, Moreno, Oscar Ruiz, Aramburu, Gonzaga Garay, Arana, Arantza Larrauri, Moreno, Angela Gómez, Feijoo, David Rodríguez, Durana Santa Coloma, Enrique Diaz, Echeveste, Maialen Aldazabal, Barrio Lopez de Ipiña, Zuriñe, Díaz, Irene Herrero, Arumí, José García, Brosa, Helena, Vela, Laura Sánchez, Zapata, Miguel Angel, Milner, Rafael Montejano, Aragón, Fernando, Veiga, Maximino José Abraldes López, Lidia, María, Conde, Gómez, Cid, María José Rodríguez, Rodríguez, María Isabel Fernández, Almuiña, Pablo, Hortelano, Varela Ana Fernández, Gallardo, Jesús Zarallo, Soriano, Rosario Cobo, Escobar, Inmaculada Lozano, Moreno, Jose Mª. Ruiz, González, Rocío Vega, Zamora, María García, Valldeperas, Ignacio Flores Moreno Xavier, Iturralde, Laura Broc, Mira, Ferran Vilaplana, Marín, Begoña Pina, Salinas, Eva, Guijarro, Martínez Jacobo González, García, Muxima Acebes, Sanchís, Sonia Aparicio, Fernández, Jonathan Cacelliere, Grijalbo, Ana Honrubia, Murillo, Ana Boned, Dolores, María, Barreda, Díaz, Rivasés, Guillermo Pérez, Pinazo, Roberto Gallego, Cholbi, Marta, Marco, Rosa Dolz, Figueroa, Marta S., Ciancas, Esther, José, Julio, López, Gonzalez, Haskour, Cesar Azrak, Sánchez, Alvaro Piñero, Sanz, Nélida Muñoz, Carreño, Ester, Ventura, Nestor, Méndez, Pablo Carnota, Vázquez, Carlos Méndez, Borrego, Carlos Torres, Villoria, Daniel Velázquez, Layana, Alfredo García, Alonso, Elena, Castillón Torre, Luis J., Muñoz, Pablo Catalán, Sempere, María Eugenia Tena, Fátima Álvarez Gil, María, García, Purificación Piñas, Eugenia, María, Bermejo, Mantrana, Javier, Francisco, Mozos, Lavid, Duran, Mónica Asencio, Martín, Estefanía Cobos, Parra, Daniel Lorenzo, Gesto, Ana Campo, Esteban, Jesús Pareja, Pilar Ruiz del Tiempo, María del, Maqueda, Mariano Rodríguez, Angeles, María, Periñan, Espiñeira
Format: Article
Language:English
Subjects:
Acuity
aflibercept
age‐related macular degeneration
Angiogenesis Inhibitors - therapeutic use
audit
benchmark standard
Bevacizumab
Blindness
Blindness - drug therapy
Demography
Eye
Health care
Humans
Internet
Intravitreal Injections
Macular degeneration
Monoclonal antibodies
national database
national dataset
neovascular AMD
ranibizumab
Ranibizumab - therapeutic use
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Retina
Spain - epidemiology
Treatment Outcome
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A
Visual Acuity
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background To study the visual outcomes of neovascular AMD (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) drugs at national level. Methods Multicenter national database of nAMD eyes treated with anti‐VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat‐and‐extend (TAE) regimens. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) ETDRS letters at baseline and subsequent visits, number of injections and visits data were collected using a validated web‐based tool (Fight Retinal Blindness!). Results 1273 eyes (1014 patients) were included, 971 treatment naïve (TN) and 302 previously treated (PT). Baseline VA (mean ± SD) was 57.5 (±19.5) and 62.2 (±17) (p > 0.001), and 24 months final VA was 60.4 (±21.2) and 58.8 (±21.1) (p = 0.326), respectively. Mean VA change at 12/24 months was +4.2/+2.9 letters in TN eyes and +0.1/−3.4 letters in PT eyes (p 
ISSN:1442-6404
1442-9071
DOI:10.1111/ceo.14054